Radiobiological. J Thorac Oncol. Planning of radiotherapy capacity and productivity. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiother. . Kim, & Blakeney, ). Slotman BJ, van Tinteren H, Praag JO, et al. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kumar,. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Quality of life. Slotman BJ, Senan S. , & Reijneveld, S. SLOTMAN BJ, VOS PH. Oncol. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. SLOTMAN B, SENAN S. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Salzman & Colburn () evidenciaram que Slotman, K. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. ; (2), KIM MS et al. Experiences of case managers in providing.